Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma

Blood Adv. 2019 Jun 11;3(11):1658-1660. doi: 10.1182/bloodadvances.2019000191.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality*
  • Time Factors

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab